As of November 6, 2026, Milestone Scientific Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 6, 2026 to July 31, 2026 (Form 8-K, July 31, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Milestone Scientific Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-31
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-25
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-06
Milestone Scientific Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-06 to 2026-07-31. Every row below is cited to the filing it comes from, and this page adds each new change as Milestone Scientific Inc. files it.
Also on the record for Milestone Scientific Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 23, 2026 | Form D, private offering | $2.15M sold | Form D page | Source |
Selling to them or working with them? See who runs Milestone Scientific Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Milestone Scientific Inc. and the records around it.
Milestone Scientific Inc. elsewhere on the record
- Form D filing Apr 2026
Watch Milestone Scientific Inc.
Get an email when Milestone Scientific Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Milestone Scientific Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Milestone Scientific Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Milestone Scientific Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-31 | Reported | not named in the filing | 8-K, 2026-07-31 | ||
| 2026-06-25 | Reported | not named in the filing | 8-K, 2026-06-25 | ||
| 2026-05-06 | Reported | not named in the filing | 8-K, 2026-05-06 |
New leaders reset buying decisions — get the Full Report on Milestone Scientific Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Milestone Scientific Inc., with the record behind each one.
Find candidates like senior executive at Milestone Scientific Inc.Every change, in the filing's words
Reported
Ms. Kelly Ulto and Mr. Greg Shilling were elected by the Board of Directors (the "Board") of Milestone Scientific Inc. (the "Company") as directors and to the committees and in the positions indicated below at the meeting of the Board held on June 20, 2026, for terms ending at the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting"), the end of the term of a vacancy filled.
- Such election occurred after the Company's proxy for its 2026 Annual Meeting had been mailed, and such persons were therefore not elected by the stockholders at the 2026 Annual Meeting.
Reported
On June 19, 2026, the Board of Directors of the Company unanimously appointed, by the directors in attendance, Kelly Ulto and Greg Shilling as independent directors of the Company.
- - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Resignation.
- Shanth Thiyagalingam, a member of the Board of Directors (the "Board") since 2025, was nominated to continue as a director but has advised the Company that he has decided to devote his full time as chief executive officer of PainTEQ and to his family, and not to run for re-election.
- He has agreed to continue as a director until June 30, 2025.
- Ms. Ulto is currently a Clinical Professor at the Gabelli School of Business at Fordham University, where she focuses on audit, analytics, and financial reporting.
- Prior to joining Fordham University in 2004, Ms. Ulto was a Senior Manager in the Audit Practice at KPMG LLP, a global accounting and professional services firm.
- Ms. Ulto received a Bachelor of Science, Public Accounting, from Fordham University, and a Master of Business Administration from Iona University.
- She is a Certified Public Accountant with over 30 years of experience in audit, financial reporting, internal controls, and risk oversight.
- Mr. Shilling is currently Partner and General Manager of 121G and 10Bridge, technology consulting and services organizations focused on digital transformation, software development, cybersecurity, and data interoperability.
Reported
The Exchange Program was undertaken in accordance with, and as expressly permitted by, the 2020 Plan and the applicable award agreements thereunder, and provides that such eligible participants may voluntarily elect to surrender some or all of their Eligible Options in exchange for newly granted stock options to purchase shares of the Company's Common Stock, at an exercise price reduced to $0.31 per share (the "Reduced Exercise Price"), which exercise price equals the closing price of the Company's Common Stock on the Effective Date (the "Repricing").
- - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- All of the Eligible Options (i) were granted under the 2020 Plan, (ii) as of the Effective Date, were held by continuing employees, (iii) had not previously been repriced and (iv) had an exercise price per share greater than the Reduced Exercise Price (the "Repriced Options").
- The Repriced Options have the same vesting commencement date and expiration date as the respective Eligible Options surrendered.
- No other changes were made to the Repriced Options as a result of the Repricing.
- The number of shares of Common Stock issuable upon the exercise of each of the Repriced Options (2.0 million shares), and the total number of shares underlying all Repriced Options (4.0 million shares), remains the same number of shares as underlying the respective Eligible Options surrendered, in accordance with the 2020 Plan.
- The Eligible Options previously had exercise prices ranging from $0.46 to $0.50 per share, and were granted in August 2025.
Tools for this story
Each opens in a new tab, filled in for Milestone Scientific Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.